Takeda, Iambic Launch Up-to-$1.7B AI Collaboration
Published: 27 Mar 2026
Author: Precedence Research
Takeda Pharmaceutical uses artificial intelligence to help design small-molecule drugs targeting cancer and gastrointestinal diseases. Its focus includes neuroscience, plasma-derived therapies, rare diseases, and vaccines.
Iambic’s CFO and chief corporate development officer stated that Iambic has demonstrated success in cancer and other domains, and believes that computational and experimental approaches are widely applicable across therapeutic domains and even therapeutic modalities.
Drug developers are increasingly turning to AI technologies to speed up discovery and cut costs, with experts predicting timelines could be halved in the coming years.
According to Towards Healthcare, the U.S. AI in biotechnology market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.57 billion in 2026 to approximately USD 12.82 billion by 2035, representing a compound annual growth rate (CAGR) of 19.55% from 2026 to 2035. This partnership has generated $1.7 billion for Lambic and gained access to NeuralPLexer, Iambic's model that predicts how drug molecules bind to proteins.
Multimodal Transformer Model
Enchant is technology-trained on dozens of data modalities and sources from across the drug discovery and development landscape. It is a computational tool designed to facilitate preclinical and clinical endpoints to make reliable predictions of human pharmacokinetics and other clinical drug properties from the early stages of discovery programs. Iambic Chief Executive Tom Miller told Reuters that understanding protein structure is critical in drug development.
About Iambic’s AI-Driven Discovery Platform
This platform enables the identification of novel chemical modalities for engaging difficult-to-address biological targets, the discovery of defined product profiles that optimise therapeutic windows, and multiparameter optimisation for highly differentiated development candidates.
Through this close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles every week.
About Iambic
The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. It is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internal and in partnership.
This collaboration will utilise Iambic’s AI models as well as the company’s fully integrated, high-throughput, and automated wet lab capabilities. These core capabilities support a rapid Design-Make-Test-Analyse cycle that can accelerate program advancement.
A recent report by Towards Healthcare highlights that the U.S. AI in biotechnology market is a deal that gives Takeda the rights to two innovative candidates that have shown promise in fighting tumours in clinical studies.